EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BRCA1/2 reversion mutations in a pan‐cancer cohort

Kohei Nakamura iD, Hideyuki Hayashi iD, Ryutaro Kawano, Marin Ishikawa, Eriko Aimono, Takaaki Mizuno, Hajime Kuroda, Yasuyuki Kojima, Naoki Niikura, Aya Kawanishi, Kei Takeshita, Shinsuke Suzuki und 11 weitere

Cancer Science · 2024-02 · 115 (2) · 635-647

DOI: 10.1111/cas.16033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2023-12. Verfasst von Kohei Nakamura und 22 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cell Science Research Foundation, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor sensitivity to platinum (Pt)‐based chemotherapy and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors is increased by homologous recombination deficiency‐causing mutations; in particular, reversion mutations cause drug resistance by restoring protein function. Treatment response is predicted by breast cancer susceptibility gene 1/2 ( BRCA1/2 ) mutations; however, BRCA1/2 reversion mutations have not been comprehensively studied in pan‐cancer cohorts. We aimed to characterize BRCA1/2 reversion mutations in a large pan‐cancer cohort of Japanese patients by retrospectively analyzing sequencing data for BRCA1/2 pathogenic/likely pathogenic mutations in 3738 patients with 32 cancer types. We identified somatic mutations in tumors or circulating cell‐free DNA that could restore the ORF of adverse alleles, including reversion mutations. We identified 12 (0.32%) patients with somatic BRCA1 ( n = 3) and BRCA2 ( n = 9) reversion mutations in breast ( n = 4), ovarian/fallopian tube/peritoneal ( n = 4), pancreatic ( n = 2), prostate ( n = 1), and gallbladder ( n = 1) cancers. We identified 21 reversion events— BRCA1 ( n = 3), BRCA2 ( n = 18)—including eight pure deletions, one single‐nucleotide variant, six multinucleotide variants, and six deletion–insertions. Seven (33.3%) reversion deletions showed a microhomology length greater than 1 bp, suggesting microhomology‐mediated end‐join repair. Disease course data were obtained for all patients with reversion events: four patients acquired mutations after PARP‐inhibitor treatment failure, two showed somatic reversion mutations after disease progression, following Pt‐based treatment, five showed mutations after both treatments, one patient with pancreatic cancer and BRCA1 reversion mutations had no history of either treatment. Although reversion mutations commonly occur in BRCA ‐associated cancers, our findings suggest that reversion mutations due to Pt‐chemotherapy might be correlated with BRCA1/2 ‐mediated tumorigenesis even in non‐ BRCA ‐associated histologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsMaleFemaleHumansBRCA1 ProteinBRCA2 ProteinGerm-Line MutationRetrospective StudiesMutationPoly(ADP-ribose) Polymerases

Stichwörter der Autor:innen

BRCA1/2PARP inhibitorhomologous recombination deficiencyplatinum-based chemotherapyreversion mutation

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kumagaya General Hospital, Kumagaya, Japan.
  • Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Diagnostic Pathology, Adachi Medical Center, Tokyo Women's Medical University, Tokyo, Japan.
  • Showa University Institute for Clinical Genetics and Genomics, Tokyo, Japan.
  • Department of Breast Oncology, Tokai University School of Medicine, Isehara, Japan.

ORCID-Profile: Kohei Nakamura, Hideyuki Hayashi, Jiichiro Sasaki, Tatsuyuki Chiyoda, Hiroshi Nishihara

Förderung

  • Cell Science Research Foundation
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Kanzawa Medical Research Foundation
  • Takeda Science Foundation
  • Uehara Memorial Foundation

Zitieren

APA

Nakamura, K., Hayashi, H., Kawano, R., Ishikawa, M., Aimono, E., Mizuno, T., Kuroda, H., Kojima, Y., Niikura, N., Kawanishi, A., Takeshita, K., Suzuki, S., Ueno, S., Okuwaki, K., Sasaki, J., Yamaguchi, M., Masuda, K., Chiyoda, T., Yamagami, W., …, & Nishihara, H. (2024). BRCA1/2 reversion mutations in a pan‐cancer cohort. Cancer Science, 115(2), 635-647. https://doi.org/10.1111/cas.16033

Vancouver

Nakamura K, Hayashi H, Kawano R, Ishikawa M, Aimono E, Mizuno T, et al. BRCA1/2 reversion mutations in a pan‐cancer cohort. Cancer Science. 2024;115(2):635-647. doi:10.1111/cas.16033

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Kohei and Hayashi, Hideyuki and Kawano, Ryutaro and Ishikawa, Marin and Aimono, Eriko and Mizuno, Takaaki and Kuroda, Hajime and Kojima, Yasuyuki and Niikura, Naoki and Kawanishi, Aya and Takeshita, Kei and Suzuki, Shinsuke and Ueno, Shinichi and Okuwaki, Kosuke and Sasaki, Jiichiro and Yamaguchi, Masatoshi and Masuda, Kenta and Chiyoda, Tatsuyuki and Yamagami, Wataru and Okada, Chihiro and Nohara, Sachio and Tanishima, Shigeki and Nishihara, Hiroshi},
  title = {BRCA1/2 reversion mutations in a pan‐cancer cohort},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {2},
  pages = {635--647},
  doi = {10.1111/cas.16033}
}
Kostenlos starten →